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A B S T R A C T
Background: Racial and socioeconomic disparities in breast cancer mortality persist. In Boston, MA, Black, Non-
Hispanic women and Medicaid-insured individuals are 2–3 times more likely to have delays in treatment
compared to White or privately insured women. While evidence-based care coordination strategies for reducing
delays exist, they are not systematically implemented across healthcare settings.
Methods: Translating Research Into Practice (TRIP) utilizes community engaged research methods to address
breast cancer care delivery disparities. Four Massachusetts Clinical and Translational Science Institute (CTSI)
hubs collaborated with the Boston Breast Cancer Equity Coalition (The Coalition) to implement an evidence-
based care coordination intervention for Boston residents at risk for delays in breast cancer care. The Coalition
used a community-driven process to define the problem of care delivery disparities, identify the target popu-
lation, and develop a rigorous pragmatic approach. We chose a cluster-randomized, stepped-wedge hybrid type I
effectiveness-implementation study design. The intervention implements three evidence-based strategies: patient
navigation services, a shared patient registry for use across academic medical centers, and a web-based social
determinants of health platform to identify and address barriers to care. Primary clinical outcomes include time
to first treatment and receipt of guideline-concordant treatment, which are captured through electronic health
records abstraction. We will use mixed methods to collect the secondary implementation outcomes of accept-
ability, adoption/penetration, fidelity, sustainability and cost.
Conclusion: TRIP utilizes an innovative community-driven research strategy, focused on interdisciplinary col-
laborations, to design and implement a translational science study that aims to more efficiently integrate proven
health services interventions into clinical practice.
1. Introduction
Inequity in breast cancer mortality among Black, non-Hispanic
women compared to White women is a well-recognized challenge. In
2014, a national study examining race-specific breast cancer mortality
rates in the 50 largest U.S. cities identified increases in Black:White
disparities, largely due to substantial improvements in White rates [1].
Boston, Massachusetts had the fifth highest rate ratio; from 1990 to
1994 to 2005–2009, the Black:White breast cancer mortality rate ratio
in Boston increased from 0.94 to 1.49. In response, a group of multi-
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sector stakeholders including the Massachusetts Cancer Registry, state
and local health departments, community advocacy organizations, and
academic health centers in Boston, where breast cancer patients receive
care, convened to explore a community-driven response to these find-
ings. This group formed the Boston Breast Cancer Equity Coalition (the
Coalition) with the explicit goal of using diverse stakeholder perspec-
tives to develop city-wide solutions for inequities in breast cancer
outcomes [2].
Early work of the Coalition explored available data to identify
modifiable targets for action. Local data for 2007–2012 showed a
Black:White mortality rate ratio of 1.36, as well as a Black:Hispanic
mortality rate ratio of 4.60 and a Black:Asian mortality rate ratio of
5.28. From 2001 to 2012, this resulted in 74 excess Black deaths among
women less than 65 years [3]. Further analyses found that compared
with White, insured breast cancer patients in Boston, Black, non-His-
panic women, and those on Medicaid were 2–3 times more likely to
have delays in initiating treatment beyond 60 days, a delay associated
with worse outcomes [4]. During this time period, Black women in
Boston received mammography screenings at the same rates, had ap-
proximately an equal likelihood of presenting with advanced disease
(4–5%), and had a lower incidence of breast cancer than White women.
These findings are consistent with a growing body of evidence that
addressing delays in the receipt of timely breast cancer treatment is one
important approach to achieving equity in cancer outcomes [5–10].
Evidence-based interventions that address barriers to timely cancer
treatment in at-risk communities exist, but are not implemented sys-
tematically across health systems [11]. The Coalition identified three
interventions most relevant to our community: 1) Patient Navigation.
This patient-centered care coordination model uses lay health workers
integrated into the healthcare team to reduce delays in cancer care for
those with social determinants of health [12–18]. 2) Patient Registries.
Clinical registries that span healthcare systems address health dis-
parities by providing a means of tracking at risk populations in need of
care [19,20]. 3) Screening for Social Determinants of Health (SDOH).
Systematic screening for SDOH that affect access to care has potential to
identify patients at risk for non-adherence and improve outcomes by
directing them to available resources that address their health-related
social needs [21,22]. Currently, we lack implementation strategies that
address the challenges in translating these findings from single clinics
into public health strategies (T3-T4 implementation translation). We
present here the methods for Translating Research Into Practice (TRIP), a
community-engaged, cluster-randomized, stepped-wedge hybrid type I
effectiveness-implementation study that aims to facilitate the transfer of
this scientific evidence into everyday practice to mitigate health dis-
parities.
2. Overall approach
Our approach aims to surmount known barriers to the im-
plementation of promising evidence-based care coordination interven-
tions by partnering four Clinical and Translational Science Institute
(CTSI) hubs that possess the necessary translational infrastructure with
an active multi-stakeholder Coalition who share a common community
health goal.
Our main hypothesis is that implementation of the TRIP interven-
tion will reduce care delivery disparities in breast cancer, and that this
approach could be applicable to addressing disparities in other regions
and health conditions. The TRIP study has three strategic aims corre-
lated with the design, execution, and dissemination of the intervention.
These aims are:
1) Conduct formative work to develop and refine delivery models that
will integrate the multi-component intervention (patient navigation,
shared registry, platform to screen/address SDOH) across six parti-
cipating academic medical centers.
2) Conduct a cluster-randomized, stepped wedge hybrid effectiveness-
implementation trial at 6 academic medical centers in Boston caring
for the largest proportions of minority, low-income women with
breast cancer to assess effectiveness and implementation of the in-
tegrated intervention.
3) Disseminate the integrated intervention to other CTSI hubs and
community-academic partnerships.
The study will be conducted in three phases, corresponding with our
Specific Aims: (1) intervention development and refinement (months
1–9); (2) rigorous testing of the intervention to evaluate both clinical
effectiveness (reducing treatment delays for women with breast
cancer), as well as its potential for implementation in real-world clinical
settings (months 9–48); and (3) widespread dissemination to the CTSI
consortium and beyond (months 36–60).
Fig. 1. TRIP organizational chart.
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3. Stakeholder collaboration
The TRIP project is a collaboration between the four Massachusetts
CTSI hubs and an established community partner, the Coalition (See
Organizational Chart, Fig. 1). Our partnership leverages com-
plementary strengths and builds on previous, synergistic work con-
ducted at each CTSI hub to address long-standing regional disparities in
breast cancer mortality. The Coalition informed all components of the
study including organizational structure. Additionally, the Multiple-PI
model in this program brings together PIs from the four Massachusetts
CTSI hubs with complementary expertise. The CTSI hubs represented
by our multiple PIs include Boston University's Community Engagement
Program, Tufts Medical Center's bioinformatics program that can har-
ness clinical data for implementation research, Harvard Catalyst's
Health Disparities Research Program, and the University of Massachu-
setts Center for Clinical and Translational Science's Implementation
Science program. In addition, our Steering Committee includes the
Executive Director of Equal Hope, a not-for-profit organization dedi-
cated to the fight against breast cancer inequalities in Metropolitan
Chicago with representation from the Chicago CTSI programs.
In addition to regularly attending quarterly Coalition meetings, two
stakeholder groups support the day to day execution and dissemination
of the intervention. Each stakeholder group includes active members
from the Coalition.
1. The Clinical Advisory Panel (CAP) includes clinical leadership at
each of the six study sites with representation from medical and
surgical oncology. The CAP meets monthly and guides the study
team on implementation strategies, facilitating local adoption, and
analyzing clinical outcomes.
2. The Boston Patient Navigator Network is an existing network of
patient navigators and their supervisors. The study team attends
these quarterly meetings to provide study updates and obtain es-
sential input on intervention components and implementation
strategies.
The Steering Committee manages oversight and coordination of
project management, research administration, publications and data
sharing, and integration of all resources needed for the project. Steering
Committee members include the PIs, the statistician, a CAP re-
presentative, a Navigator Network representative and a Chicago re-
presentative.
4. Experimental design
This study is a Type 1 hybrid clinical effectiveness-implementation
trial [23] which aims to improve timely, quality breast cancer care
among at-risk breast cancer patients through implementation of an
integrated, evidence-based patient navigation intervention. Our pri-
mary outcome of clinical effectiveness will be evaluated using data
abstracted from Electronic Health Records (EHR). Our secondary out-
come of intervention implementation uses mixed methods to measure
intervention uptake in real world clinical settings.
We will use a prospective, stepped wedge cluster randomized design
[23–26] to study implementation of the evidence-based intervention
across six participating academic medical centers in Boston. In a
stepped wedge design there is no randomization at the patient level, but
participating sites (medical centers) are randomized with respect to the
timing at which they ‘step’ or cross over from the control condition to
the intervention. As pictured in Fig. 2, the pragmatic stepped wedge
study design involves a sequential roll-out of the intervention across the
six participating sites over three-month intervals or “steps” where
crossover occurs. Historical control data will be collected from each site
for a minimum of 21 months and maximum of 36 months prior to in-
tervention roll-out, depending on their assigned crossover. Sequential
crossover to the intervention at participating sites will occur every three
months over a 15-month period, followed by an additional 24 months
of full study intervention period.
5. Study setting
The six academic medical centers we have partnered with are Beth
Israel Deaconess Medical Center, Boston Medical Center, Brigham and
Women's Faulkner Hospital, Dana-Farber Cancer Institute,
Massachusetts General Hospital and Tufts Medical Center. These six
academic medical centers have been identified by data from the
Massachusetts Cancer Registry as sites that care for over 90% of women
with breast cancer who are at risk for poor outcomes in Boston, in-
cluding Black or Hispanic, Non-English speaking, and/or have no in-
surance or public health insurance. As summarized in Fig. 2, we esti-
mate accrual of 1100 study subjects, including approximately 511
historical controls and 589 intervention subjects across the six sites.
6. Eligibility criteria
The target population includes vulnerable inner-city women with
risk for delay in breast cancer care. Massachusetts (MA) Cancer Registry
data identified the following characteristics of Boston residents with
greatest delays in breast cancer treatment: Black, Hispanic, non-English
speaking, and public health insurance. All women with breast cancer
diagnosed at a participating study site during the study period will be
eligible for inclusion if they meet all three study criteria: 1) women
greater than 18 years of age; 2) reside in the City of Boston; and 3) have
one or more of the following risk factors for delays in care: Black race
and/or Hispanic ethnicity, primary spoken language is not English,
and/or have public insurance or uninsured status at the time of diag-
nosis.
7. Enrollment
As this is a health system level intervention, all eligible women
receive the intervention. Navigator protocols include tailored workflow
maps that specify how each navigator identifies newly diagnosed breast
cancer cases who meet TRIP eligibility criteria within each of the six
clinical sites. We expect every eligible patient to be enrolled, as the
TRIP intervention will be implemented as a standard of care at each
participating site.
8. The intervention
The intervention includes three integrated components:
1. Patient Navigation services following standard operating procedures
that are guided by the Principles of Care Management [27] in col-
laboration with a network of navigators across the six health sys-
tems. This includes: a) identifying women eligible for navigation
services; b) identifying barriers to initiating timely cancer care ser-
vices, with a particular emphasis on social barriers; c) providing
assistance to address these barriers through local and regional re-
sources; and, finally, d) tracking women over time across the par-
ticipating clinical sites to ensure they complete their entire course of
cancer care. A TRIP navigation protocol was designed by the study
team to reflect evidence-based best practices for oncology naviga-
tion [28]. The innovation here is the integrated network of navi-
gation across regional health systems.
2. A real time patient registry that is shared across the six health sys-
tems. The registry was built using the HIPAA compliant REDCap
platform through collaboration with clinical providers, patient na-
vigators, informatics specialists, and experts from the REDCap team
at Vanderbilt University. Navigators enter basic demographic in-
formation and track screening and referrals for social determinants
of health (see 3. below). Clinical information is kept to a minimum
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in an effort to reduce redundancy with the EHR and minimize
double data entry. This navigator tool produces reports that prior-
itize the navigator's caseload based on pre-determined markers of
timely care (e.g. days since diagnosis) and directs them with an
actionable list of patients with pending navigation needs. Some of
these functions require manual manipulation of the data using SAS
and uploading that data back into REDCap. The registry allows
communication between navigators, specifically around patients
receiving care in more than one location or transferring care be-
tween institutions, to prevent delays and gaps in care. Navigators
can message each other directly through REDCap. They can also
write notes about appointments and treatment received. Research
staff are also able to use the registry as a monitoring tool to track
navigator activity.
3. A systematic screening and referral system to identify and address
SDOH needs. At baseline and 3 months navigators conduct a sys-
tematic screening for social needs across 9 social domains including:
housing insecurity, food insecurity, paying for basic utilities, family
caregiving, legal, transportation, paying for treatment, education,
and employment. We will partner with Aunt Bertha, a web-based
social network platform, to develop a TRIP-specific screening and
referral system to support navigators in connecting patients with
available social services. The Aunt Bertha [29] platform is an online
network of thousands of verified social service programs including
nonprofits and social care providers who serve the Boston commu-
nities. Navigators will work with patients to identify the most
pressing domains and then identify available community services to
address each domain. At each contact, the navigators check on the
status of referrals and assess whether a woman would like to receive
additional referrals from similar or different domains.
The planned process of rolling out the integrated intervention be-
gins with partnering with a clinical oncology champion at each site to
identify existing navigation staff and document baseline navigation
workflow. We plan to use several evidence-based implementation
strategies [30] to promote intervention adoption into existing work-
flows including: stakeholder engagement, development of a standar-
dized intervention protocol, iterative training and technical assistance
on evidence-based protocol, and continuous monitoring and feedback.
Once a navigator has been designated as the TRIP study navigator and
completed their required trainings, they are able to start navigating
patients under the TRIP protocol [28]. Navigators will prospectively
identify newly diagnosed breast cancer patients meeting eligibility re-
quirements and initiate the protocol. Key protocol activities include
systematic and longitudinal screening for the social determinants of
health, use of a web-based platform to identify resources and initiate
referrals to address social issues that might interfere with cancer care,
and use of a shared patient registry to communicate with navigators
from other participating study sites in the event a study subject trans-
fers care during the intervention period.
9. Study outcomes
9.1. Outcome measures
Our study is powered on the primary clinical effectiveness outcome,
time to initiation of cancer treatment. This is a continuous outcome de-
fined as the number of days from diagnosis (Time 0) to treatment in-
itiation (Time 1). Treatment initiation is defined as receipt of either
surgical, radiation, or systemic therapy. Table 1 displays the specific
data elements that will be used to define treatment initiation.
Secondary clinical outcomes include select measures of Guideline
Concordant or Quality cancer care, as defined jointly by the Commission
on Cancer and the National Comprehensive Cancer Network [13].
Specific measures of guideline concordant/quality care (yes/no) are
defined in Table 2.
Implementation outcomes include acceptability, local adoption/
penetration, fidelity to the intervention protocol, sustainability and cost
of the intervention across each site [31]. Acceptability will examine
perceptions of the intervention components among patient navigators
and other members of site navigation teams. Adoption/penetration will
measure the reach and integration of TRIP and its practices throughout
Fig. 2. Stepped-wedge study design: Schedule of events for site roll out in the intervention.
Table 1
Data Elements for “Time to Initiation of Primary Breast Cancer Treatment”
Calculations.
Time period Date of
Time 0 First definitive tissue diagnosis (i.e. biopsy)
Time 1 First definitive treatment, including any of the following:
Definitive surgical procedure (lumpectomy or mastectomy)
External radiation therapy session, neoadjuvant chemotherapy
infusion, prescription for neoadjuvant hormone therapy
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each institution. Fidelity is being conceptualized as navigator ad-
herence to the standard operating procedures. Sustainability will ex-
amine the extent to which TRIP is maintained or institutionalized
within the academic medical center's ongoing operations. Finally, the
cost of implementing the integrated TRIP intervention components will
be captured through microcosting measurement [31–35].
10. Data sources
TRIP uses multiple data sources as outlined in Table 3. The EHR will
serve as the data source for all socio-demographic and clinical covari-
ates, as well as the primary and secondary clinical effectiveness out-
comes. EHR data will be captured in two ways: (a) automated extrac-
tion will capture all demographic variables and some discrete clinical
data; and (b) manual abstraction to collect the complex data elements
required to create treatment variables.
The main sources of data for our implementation outcomes include:
the REDCap registry, the SDOH screening platform and qualitative data
collected through observations, interviews, and surveys. The REDCap
registry and SDOH screening platforms will provide quantitative mea-
sures of fidelity to the intervention protocol, as documented by the
navigators in their day to day activities. Navigator interviews will
measure acceptability, and local adoption/penetration. Observations of
navigators in the field will further assess fidelity, as well as local
adoption/penetration. Focus groups with academic medical center
leadership and the study's clinical advisory panel at month 24 of the
intervention period will provide data to further examine acceptability,
adoption and sustainability. Finally, the use of surveys will determine
the amount of time patient navigators contribute for TRIP patients as
well as time spent by study personnel in the development of interven-
tion components, which will inform our cost estimates.
11. Statistical analysis of effectiveness outcome
Our comparative analyses between the intervention and usual care
(historical control) groups will employ the intent-to-treat principle. The
primary outcome is time to initiation of treatment. We will employ Cox-
type proportional hazards-based models for correlated time-to-event
data. These models will account for clustering by study site or the in-
clusion of a random intercept. We will examine the proportional ha-
zards assumption using plots (survival, −log(log), and Schoenfeld re-
siduals), as well as statistical tests including Kolmogorov-type
supremum tests and the inclusion of interaction term of intervention
group with the log of follow-up time in the model. Other potential
modifiers of the effectiveness of intervention, confounders, or covari-
ates can be added to this model as fixed effects. Although we do not
expect effect modification in the study data, we will examine the po-
tential for such effects (interaction) through the use of stratified ana-
lyses and the inclusion of interaction terms with study group in our
statistical models. A priori candidate effect modifiers include race/
ethnicity, cancer stage and type, patient age, and insurance status.
Statistically significant interactions with intervention will be retained
and the nature of heterogeneous intervention effects will be estimated
using the interaction model. Fidelity data will also be linked with ef-
fectiveness outcomes in order to determine the extent to which it in-
fluences the ability of the intervention to improve patient outcomes.
We will calculate the costs of implementing the intervention, in-
cluding costs associated with developing and implementing the registry
and screening systems, training and materials costs, and navigator
costs. Staff costs of implementing the program will be calculated by
multiplying the amount of time spent by an hourly wage estimate. We
will provide a range of cost estimates that users can use to guide their
own implementation estimates.
Table 2
Secondary clinical outcomes: Guideline-Concordant Care Quality Measures.
Treatment domain CoCa Criteria for quality cancer care
Radiation Radiation therapy administered within 365 days of diagnosis for women <70 years receiving breast conserving surgery
Radiation therapy administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥4 positive regional
lymph nodes
Chemotherapy Combination chemotherapy administered within 120 days of diagnosis for women <70 with AJCC T1c N0 M0, or Stage II or III Estrogen Receptor and
Progesterone Receptor (ER and PR) negative breast cancer
Hormonal Tamoxifen or aromatase inhibitor administered within 365 days of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ER and/or PR+ breast
cancer.
a CoC=Commission on Cancer; https://www.facs.org/quality%20programs/cancer/ncdb/qualitymeasures
Table 3
Data sources and their corresponding role in study analyses.
Source Study domain Data variables Data collection
EHRs Covariates Race/ethnicity, age, insurance status, comorbid
conditions, cancer stage
Automated extraction of discrete EHR fields
Effectiveness (outcomes) Time to treatment (# days) Manual abstraction using standardized form
Guideline-concordant treatment (yes/no)
Registry Implementation Fidelity to navigation protocol. e.g. completed
intake, communicated with other navigators
Aggregate reports from REDCap platform
SDOH platform Implementation Fidelity to protocol. e.g. completed systematic screen
at baseline and 3 months y/n
Aggregate reports from SDOH Screening platform
Navigator interviews Implementation Acceptability, Adoption/Penetration Transcripts from one on one structured interviews with TRIP
Navigators
Navigator observations Implementation Fidelity, Adoption/Penetration Field observations of TRIP navigators in the clinical setting
Focus groups Implementation Acceptability, Adoption/penetration, Sustainability Transcripts from focus groups with hospital administrators and
clinicians
Surveys Implementation Cost Survey (study personnel) of costs associated with developing and
implementing training, registry and SDOH screening platform;
Survey of time spent on TRIP related activities (navigators and
supervisor)
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12. Qualitative analyses
At least two members of the study team will independently review
transcripts from each of the first three interviews and focus groups to
identify important concepts that emerge and create a codebook used for
subsequent interviews. Then, two coders will independently code in-
terviews for agreement analysis. Coders will meet twice monthly to
review code interpretation and to discuss new codes. Disagreements
about code meanings will be resolved by consensus. Thematic analysis
will focus on the perceptions of acceptability, adoption/penetration and
sustainability related to implementing the TRIP standard of care. After
coding is finalized and consensus has been reached, codes will be re-
viewed to generate cross-cutting themes within each site. Similarities
and differences in the themes will be compared across sites. This will
allow us to identify the extent to which TRIP is seen as acceptable or
having substantial reach within the health system among different sites.
13. Sample size and power
Based on Massachusetts Cancer Registry data, we expect approxi-
mately 1100 total patients over the full intervention period. With ap-
proximately 500 historical control patients, and 550 intervention pa-
tients. Sample size estimates assume 80% power and a two-sided alpha
of 0.05 for cross-sectional stepped wedge studies comparing interven-
tion to usual care in two-group statistical analyses. This method in-
corporates information on the number of steps used in the stepped
wedge design, the number of subjects per time period, and the degree of
clustering via the intra-class correlation coefficient (ICC) to compute
the design effect. A sample size of 220 subjects per group in a log rank
test will provide 80% power at a two-sided alpha of 0.05 to detect a
difference in the proportion of subjects with treatment at time, t, of
81% in the intervention group compared to 70% in the usual care
group, a level estimated from recent data from the clinical sites for the
planned study. This difference yields a hazard ratio of 1.75, a clinically
meaningful effect size for time-to-treatment post-diagnosis. Based on
our planned number of steps, enrollment per study period, and a rea-
sonable ICC of 0.1, the design effect is 2.29. Thus, we will need to enroll
and follow at least 1008 subjects to provide 80% power for analysis of
intervention effectiveness.
14. Dissemination
In year 5, we will develop a web-based multi-media intervention
toolkit that describes background information, procedures and proto-
cols, intervention components and required resources that will be made
available at no cost to investigators at CTSI hubs, other academic in-
stitutions, and community organizations.
15. Discussion
The TRIP study addresses a critical gap in the translational research
enterprise, namely the transfer and application of scientific evidence
that is necessary to mitigate health disparities into everyday practice. It
is the first ever city wide implementation study aimed at coordinating
oncology care delivery across multiple academic medical centers. TRIP
includes an integrated, multi-component intervention that builds from
preliminary work of the investigative team and their community
partner, the Coalition. Using a community engaged approach that in-
cludes governance by multiple stakeholder teams, TRIP is designed to
overcome barriers to widespread implementation and dissemination of
evidence-based practices that will improve the delivery of guideline-
concordant care to vulnerable populations. TRIP draws upon the prin-
ciples of implementation science to understand how to systematically
facilitate deployment and utilization of three evidence-based ap-
proaches into one integrated model of care to improve the quality and
effectiveness of care delivery, in this case for minority and/or low-
income women with breast cancer.
TRIP utilizes a stepped-wedge study cluster randomized design that
is increasingly being used in the evaluation of service delivery type
interventions [24]. The design involves random and sequential cross-
over of clusters from control to intervention until all clusters are ex-
posed. We considered several alternative designs. While the primary
target of the intervention is the patient, the intervention will be de-
livered by navigators within a given health care system. Thus, in-
dividual or provider level randomization is not feasible. The decision to
choose a randomized stepped wedge, versus a standard group-rando-
mized trial, was chosen for two commonly reported reasons. One is that
our clinical and public health partners prefer the intervention to be
rolled out to all sites/navigators and to not have pure control sites. The
second is that a stepped wedge design allows us to maximize our re-
sources, spacing out the roll out of the navigator intervention and
technology-based components over time. Additional benefits of this
approach are the inclusion of contemporaneous controls to minimize
the impact of temporal trends on outcomes and the ability to in-
corporate sites that differ in size.
Our scientific premise is that there are critical evidence and delivery
gaps that promote disparities in the clinical outcomes of women with
breast cancer. A major focus of the National Center for Advancing
Translational Science within the National Institutes of Health is for the
CTSI hubs to work together to address such delivery gaps and bottle-
necks, with specific attention to those that affect special populations
and contribute to health disparities. This translational project has sev-
eral innovations:
1. Our collaborative approach is innovative. The engagement of com-
munities in T4 research focused on health system clinical care de-
livery is necessary to implement an effective intervention and en-
sure broad translation to communities at risk. Using community
engagement approaches in partnership with a community-led
Coalition has great potential to address the known barriers to
achieving information sharing and implementation of the evidence
across diverse health systems. The Coalition includes stakeholders
who provide leadership representative of the population and the
ability to make practice improvements in real life clinical settings.
2. Our inclusion of all major health care systems in the geographic area
is innovative. While multi-site trials are common, few are designed
for systems to collaborate to address the implementation of evi-
dence-based approaches to address the needs of an entire commu-
nity that has care fragmented across so many academic medical
centers and clinical sites. Our hypothesis that some of the delays in
care reflect transitions between health care systems, for either
structural, insurance coverage or patient preference reasons. This
approach if successful, can be translated to other locations and other
health care conditions where disparities in outcomes are prominent
and persistent.
3. Likewise, our regional registry is innovative. It will provide clinical
providers, practices, and healthcare systems with timely metrics on
the processes of navigation. The ability to share standardized navi-
gation data within and across health systems is innovative and ne-
cessary – as our preliminary work suggests 49% of Black women in
Boston transfer their care within these health systems during their
cancer treatment. This infrastructure will accelerate scientific and
public health progress in monitoring disparities.
4. Our systematic approach to screening and intervention for SDOH is
innovative. Addressing social needs that may deter women from
engaging with their care or lead to poorer health status is a crucial
step to addressing disparities in care. By integrating systematic
screening and referral to resources to address social determinants of
health, we will examine a novel, generalizable model using an
electronic platform that is integrated with the provision of care.
5. Our study design is innovative. While each individual component of
the intervention is evidence based and not innovative, the TRIP
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intervention unites the three components of navigation, shared pa-
tient registries, and standardized SDOH screenings in a unique and
novel way. The long-term goal of this study is to make available an
evidence-tested, integrated intervention that can be implemented
and effective in complex delivery systems. The pragmatic stepped
wedge study design will allow us to test effectiveness and im-
plementation outcomes in the context of complex intervention de-
livery systems while also maintaining scientific rigor.
6. This study provides a model of how community-academic partner-
ships can drive innovations in information sharing and systems
implementation to address health disparities. Results of this study
will demonstrate the efficacy in a city-wide, integrated intervention
model that can be applied to other regions and other health condi-
tions. Inclusion of a specific aim devoted to widespread dissemina-
tion will make the study findings, tools and lessons learned available
to the entire CTSI network and beyond.
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